Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients

ABSTRACT We analyzed serially collected serum samples from healthy adults who underwent BNT162b2 vaccination to elucidate the association between spike (S)-IgG antibody titers determined by ELISA using the WHO international standard (NIBSC code 20/136) and neutralizing antibody titers against three live SARS-CoV-2 variants. This study included 53 health care workers who received two doses of the BNT162b2 vaccine. S-IgG and nucleocapsid (N)-IgG antibody titers were measured by ELISA. Neutralizing (NT) antibody responses against three variants (Wuhan D614 G: KUH003, Alpha, and Delta) were evaluated before and after the first and second vaccination. N-IgG were not detected in any serum samples. S-IgG antibody titers remarkably increased after two BNT162b2 vaccine doses in all participants. S-IgG antibody titers were strongly correlated with NT titers against three variants of live viruses: KUH003 (r = 0.86), Alpha (r = 0.72), and Delta (r = 0.84). Serum samples from participants after one dose of BNT162b2 neutralized Alpha efficiently (median titer, 113.0), but median NT titers against KUH003 and Delta variants were lower, 57.0 and 28.0, respectively (p < .01). Two doses of the BNT162b2 vaccine elicited a strong immune response in this study. The second dose was required for induction of a strong booster effect. Serum collected from BNT162b2 vaccine recipients contained significantly lower neutralizing activity against Delta than that of against KUH003 (p < .0001) and Alpha (p < .0001). If a new variant emerges, live virus-based NT titers should be examined in serum obtained from vaccine recipients to evaluate vaccine efficacy for protection against infection.

[1]  S. Vermund,et al.  Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination , 2022, Nature Medicine.

[2]  M. Rämet,et al.  Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age , 2021, The New England journal of medicine.

[3]  A. Ryo,et al.  Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay , 2021, Journal of Infection and Chemotherapy.

[4]  A. Krüttgen,et al.  Two novel SARS-CoV-2 surrogate virus neutralization assays are suitable for assessing successful immunization with mRNA-1273 , 2021, Journal of Virological Methods.

[5]  D. Montefiori,et al.  Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis , 2021, Nature Medicine.

[6]  J. Dogné,et al.  Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers , 2021, Vaccines.

[7]  N. Z. Canturk,et al.  Comparison of an inactivated Covid19 vaccine-induced antibody response with concurrent natural Covid19 infection , 2021, International Journal of Infectious Diseases.

[8]  B. Mustanski,et al.  Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history , 2021, Scientific Reports.

[9]  M. C. Muenker,et al.  Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity , 2021, Nature.

[10]  Frances E. Muldoon,et al.  Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 , 2021, Nature.

[11]  William T. Harvey,et al.  Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination , 2021, medRxiv.

[12]  D. Wesemann,et al.  Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants , 2021, Science.

[13]  G. Ciliberto,et al.  Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine , 2021, EClinicalMedicine.

[14]  P. Dormitzer,et al.  Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents , 2021, The New England journal of medicine.

[15]  Yangzhong Zhou,et al.  COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says , 2021, Frontiers in Immunology.

[16]  H. Asamura,et al.  Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening , 2021, Cell Reports.

[17]  Scott L. Bain,et al.  COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study , 2021, The Lancet.

[18]  K. Makar,et al.  WHO International Standard for anti-SARS-CoV-2 immunoglobulin , 2021, The Lancet.

[19]  R. Taube,et al.  SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera , 2021, Cell Host & Microbe.

[20]  William T. Harvey,et al.  Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies , 2021, Nature.

[21]  Paige G. Wickner,et al.  Acute Allergic Reactions to mRNA COVID-19 Vaccines. , 2021, JAMA.

[22]  D. Fremont,et al.  Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization , 2021, Cell Host & Microbe.

[23]  P. Dormitzer,et al.  Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera , 2021, Science.

[24]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[25]  E. Walsh,et al.  Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.

[26]  E. Walsh,et al.  Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults , 2020, Nature.

[27]  M. Van Ranst,et al.  Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs , 2020, Clinical Microbiology and Infection.

[28]  Xuguang Li,et al.  The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity , 2020, Cell.

[29]  K. To,et al.  Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan , 2020, Emerging microbes & infections.

[30]  J. Peiris,et al.  The M, E, and N Structural Proteins of the Severe Acute Respiratory Syndrome Coronavirus Are Required for Efficient Assembly, Trafficking, and Release of Virus-Like Particles , 2008, Journal of Virology.